読み込み中
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
前日終値
$5.88
+$0.05 · +0.86%
時間外
$5.82
−$0.06 · -1.02%
10月8日 19:57 ET
日中の時刻はETです。市場データは遅延する場合があります。
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
日中レンジ
現在 $5.88
52週レンジ
現在 $5.88
日中の時刻はETです。市場データは遅延する場合があります。
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
日中レンジ
現在 $5.88
52週レンジ
現在 $5.88
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 63.42万 USD | — | — | — | — |
| 販売・一般管理 | 651.21万 USD | 554.02万 USD | 63.13万 USD | 53.4万 USD | 110.91万 USD |
| 営業費用 | 714.63万 USD | 554.02万 USD | 63.13万 USD | 65.7万 USD | 110.91万 USD |
| 受取利息 | — | — | — | 128.05万 USD | — |
| 支払利息 | 231.4万 USD | 35.66万 USD | 7.62万 USD | — | — |
| 減価償却費と償却費 | — | — | — | — | 110.91万 USD |
| 営業利益 | −714.63万 USD | −554.02万 USD | −63.13万 USD | −65.7万 USD | −110.91万 USD |
| 純利益 | −1055.17万 USD | −615.04万 USD | −70.75万 USD | 123.34万 USD | −110.9万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年8月24日 | 1:50 | — | — |
発効済み 2026年8月24日
1:50
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
